Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
56
resultados
Última actualización
30/11/2025 [07:17:00]
Resumen de: WO2024231628A1
The invention relates to a method for the early in vitro diagnosis of a neurodegenerative disease in a human or an animal subject, the method comprising the step of detecting the presence of at least one marker chosen from among forms derived from amyloid beta peptides (Aβ) chosen from among the oligomers of these peptides and the prefibrillar and fibrillar aggregate forms of these peptides, and forms derived from phosphorylated tau proteins chosen from among the hyperphosphorylated forms of these proteins, the aggregate forms of these proteins and the modified phosphorylated tau proteins resulting from one or more post-translational modifications, the presence of the one or more markers being detected in a stool sample from this subject.
Resumen de: US2025361504A1
The present disclosure relates, in general, to methods of preparing a spatial proteome and/or transcriptome sequencing library. The spatial proteome and/or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.
Resumen de: US2025359753A1
Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
Resumen de: CN120457337A
The present disclosure provides a method of preparing a biosensor for detecting Alzheimer's disease biomarkers, comprising depositing an alumina film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing an electric contact part Cr/Au on the Al2O3/Si substrate through a thermal evaporator, and forming a source electrode, a drain electrode and a planar grid electrode on the Al2O3/Si substrate; providing double-layer graphene on the Al2O3/Si substrate through thermal annealing in a vacuum environment; performing low-damage plasma treatment (LDPT) on the double-layer graphene with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite material on the Al2O3/Si substrate; an antibody is immobilized on the surface of a GO/G layered composite material by a reaction between an amine group of the antibody and a carboxyl group of GO of the GO/G layered composite material, where the antibody is specific for p-tau217 protein.
Resumen de: WO2025240658A1
Neprilysin inhibitors are used for the treatment of patients with Alzheimer's disease or other proteinopenic diseases of the CNS. The patients selected for therapy may be selected based on confirmed biomarker diagnosis of disease, along with a reduced Aβ level.
Resumen de: US2025355002A1
The invention provides antibodies and binding fragments thereof that specifically binds to TDP-43 cryptic exon-encoded neoepitopes, and methods of use thereof. The methods of use include methods of detecting TDP-43 loss of function, methods of detection and/or diagnosing TDP-43 associated diseases, and methods of monitoring disease progression and/or response to therapy. The invention also provides a kit including the antibodies and binding fragments thereof.
Resumen de: US2025355001A1
The invention relates to an in vitro method for detecting a tau protein fragment in a sample from a patient wherein the amino acid sequence of the fragment consists of amino acid residues within residues 113 to 379 of SEO ID NO: 1. The method may use a specific binding molecule, such as an antibody, directed to key epitopes of tau. The invention may find applications in diagnostics of tauopathics.
Resumen de: US2024310389A1
This document provides methods and materials related to screening for and treating Alzheimer's disease (AD), including late-onset Alzheimer's disease (LOAD).
Resumen de: WO2024148357A2
U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.
Resumen de: JP2025094219A
To provide TDP-43-specific binding molecules for diagnosing, preventing, ameliorating, and/or treating diseases, disorders, and/or abnormalities associated with TDP-43 aggregates, or TDP-43 proteinopathies.SOLUTION: Provided is a TDP-43 binding molecule that is an antibody or an antigen-binding fragment thereof, which binds misfolded aggregated TDP-43 and non-aggregated physiological TDP-43, or a humanized variant thereof.SELECTED DRAWING: None
Resumen de: US2025347684A1
Provided herein is a method for treating a human subject with Alzheimer's Disease (AD) having an AD metabolomic phenotype, the method comprising: obtaining or having obtained a blood sample from the human subject with Alzheimer's disease; measuring the levels of metabolites in the blood sample; applying an algorithm to the measured metabolite levels, the algorithm generating a metabolomic score based on a comparison of the measured metabolites levels to reference metabolites levels; identifying the human subject with Alzheimer's Disease as having an AD metabolomic phenotype based on the metabolomic score; wherein the algorithm is selected from a machine learning algorithm, a clustering algorithm, a random forest algorithm, a support vector machines algorithm, a radial basis function algorithm and a combination thereof.
Resumen de: US2025346956A1
In some aspects, the present disclosure provides a method for determining a risk or state of a neurodegenerative disease of a subject. In some embodiments, the method compriseses detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: E7EUF1, O94812, P02549, P02730, P05019, P05154, P05546, P13497, P16157, P16452, P17936, P24593, P27918, P35858, P41218, Q12797, Q13214, Q13822, Q8NI99, Q96IY4, Q99715, Q9BXN1, Q9H0B8, or a proteoform thereof. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: P54803, P14625, P30043, P00742, A0A0D9SG88, Q5TFM2, P54803, P54803-3, P54803-4, P04196, or a proteoform thereof. In some embodiments, the method comprises determining the risk or state of the neurodegenerative disease of the subject based on the presence of the biomarker in the biological sample.
Resumen de: CA3242558A1
Aspects of the application relate to methods and systems for obtaining information regarding multiple amino acids in a polypeptide based on binding interactions between the polypeptide and one or more amino acid recognizers. Kinetic signature information may be obtained from a series of signal pulses indicative of a series of binding events between one or more amino acid recognizers and an amino acid of a polypeptide (e.g., a terminal amino acid, an internal amino acid). The kinetic signature information (e.g., pulse duration, interpulse duration, recognition segment (RS) duration, intersegment duration) may be used to determine one or more chemical characteristics (e.g., identity, modification) of multiple amino acids of the polypeptide.
Resumen de: MX2024001835A
Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD 163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
Resumen de: US2025341530A1
The present disclosure relates to immunoassays for NF-L performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L determinations at concentrations indicative of the condition.
Resumen de: AU2024274218A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Resumen de: WO2025231348A1
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, treatment, and identification of the presence of pretangles in a subject. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Resumen de: US2025340941A1
Disclosed herein are methods for assaying a potential drug candidate for the treatment, prevention, reduction or amelioration of neurodegenerative diseases and disorders. Some aspects pertain to stimulating a cell to induce a phenotype characteristic of a neurodegenerative disease or disorder and contacting the cell with a potential drug candidate and determining a responsive change, wherein a decrease or loss in the phenotype is indicative that the drug candidate is capable of treating, preventing, reducing or ameliorating neurodegenerative diseases or disorders.
Resumen de: US2025339434A1
A process for treating a human subject with a neurologic disorder comprises obtaining a sample of the human subject. The sample is contacted with an assay for detecting a presence of soluble folate binding protein (sFBP), one or more single nucleotide polymorphism (SNP) in folate or related one-carbon metabolism genes, or both. Based on the whether there is a presence of sFBP, a presence of SNPs, an amount of folate receptor alpha autoantibody (FRAA) (i.e., FRAA titer), or a combination thereof in the sample, a treatment including a folate is created. The treatment is then administered to the human subject.
Resumen de: EP4644569A2
The present disclosure provides methods and systems for mapping gene and protein expression in a cell (i.e., mapping gene and protein expression within the same cell simultaneously). The present disclosure also provides methods for diagnosing a disease or disorder (e.g., a neurological disorder such as Alzheimer's disease) in a subject. Methods of screening for a candidate agent capable of modulating gene and/or protein expression are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder, such as Alzheimer's disease, in a subject in need thereof. A plurality of oligonucleotide probes, which may be useful for performing the methods described herein, are also described by the present disclosure, as well as kits comprising any of the oligonucleotide probes described herein. Additionally, the present disclosure provides methods, apparatuses, and non-transitory computer-readable storage media for identifying spatial variations of cell types in at least one image.
Resumen de: MX2025011654A
The present invention relates to anti-a-synuclein antibodies, which preferentially recognize a-synuclein aggregates, and uses for detection, diagnosis, and/or treatment or prevention of a variety of diseases or disease symptoms related thereto due to accumulation of a-synuclein aggregates by using the anti-a-synuclein antibodies.
Resumen de: MX2025011444A
The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes for use in treating or preventing diseases associated with extracellular trap release from cells, such as Neutrophil Extracellular Trap (NET)- associated pathologies (NET associated pathology) or Eosinophil Extracellular Trap (EET) -associated pathologies (EET-associated pathology), wherein the methods comprising administering at least one dose of the antibody at a specific concentration. The invention also provides the methods themselves. The NET-associated pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, Anti-phospholipid Syndrome, Bechet's disease, spondylitis, spondyloarthropathy, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, nongranulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or other NET-associated pathologies such as wound healing in diabetes, cancer, cancer metastasis, and transplant organ health in vivo or ex vivo. The invention a
Resumen de: JP2025029000A
To provide a method for detecting a neurodegenerative disease of a subject, and a method for treating the subject.SOLUTION: A method includes a step of detecting a level of exosome-associated coagulation biomarkers in a specimen collected from a subject. In the method, an increased level of exosome-associated coagulation biomarkers compared to a reference level indicates that the subject is suffering from a neurodegenerative disease.SELECTED DRAWING: None
Resumen de: AU2024235526A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Nº publicación: AU2024284125A1 30/10/2025
Solicitante:
MCLAUGHLIN RES INSTITUTE FOR BIOMEDICAL SCIENCES
MCLAUGHLIN RESEARCH INSTITUTE FOR BIOMEDICAL SCIENCES
Resumen de: AU2024284125A1
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
BOPI
Sede Electrónica
